Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1792879 | 0.92 | CHRNA7 (0.56) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL928031 | 0.85 | CHRNA7 (0.56) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL930768 | 0.83 | CHRNA7 (0.59) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL927572 | 0.82 | KCNH2 (0.62) | CHRNA7KCNH2HTR3ACHRNB2CHRNA4 | |
| SCHEMBL928039 | 0.81 | CHRNA7 (0.42) | CHRNA7KCNH2HTR3A | |
| SCHEMBL928628 | 0.81 | CHRNA7 (0.41) | CHRNA7KCNH2HTR3A | |
| SCHEMBL927444 | 0.81 | CHRNA7 (0.41) | CHRNA7KCNH2HTR3A | |
| SCHEMBL929028 | 0.81 | CHRNA7 (0.41) | CHRNA7KCNH2HTR3A | |
| SCHEMBL927767 | 0.79 | CHRNA7 (1.00) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL18016323 | 0.79 | CHRNA7 (1.00) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | claimed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-7994223-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LABORATORIES (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286109-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | CHRNA7 9/4885KCNH2 1058/4885CSNK1D 463/4885 |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885KCNH2 3938/4885CSNK1D 3595/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | CHRNA7 13/4885KCNH2 1020/4885CSNK1D 1460/4885 |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885KCNH2 826/4885CSNK1D 728/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CHRNA7 1/4885KCNH2 340/4885CSNK1D 511/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNA7 1/4885KCNH2 765/4885CSNK1D 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.